Currently, therapies for MM mainly include proteasome inhibitors (PIs) (such as bortezomib and carfilzomib), immunomodulators (such as lenalidomide and pomalidomide), and immune-related therapies [such as CD38 and B cell maturation antigen (BCMA) monoclonal antibodies, bispecific monoclonal antibodies], and chimeric antigen receptor T cell (CAR-T) therapy [9–14]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.